AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 162 min read$CELC

BAKER BROS. ADVISORS LP sold $317.8M of CELC (indirect holdings)

BAKER BROS. ADVISORS LP sold 3,100,000 indirectly-held shares of Celcuity Inc. (CELC) at $102.50 ($317.75M total) across 2 trades on 2026-07-14.

Original reporting
SEC EDGAR · BAKER BROS. ADVISORS LP
Published Jul 16, 2026, 9:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CELC
Neutral
medium confidence
Mentioned
$CELC
Relevance
9/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CELCNeutralLow
01

Why it matters

A reported open-market sale of 3.1M shares at $102.50 totals about $317.75M, which can influence short-term sentiment but does not, by itself, change company fundamentals.

02

Market read

Traders may monitor CELC for follow-on selling signals, but the text provides no new operational catalyst or guidance change.

03

What to watch

No 10b5-1 plan is stated, but the filing does not provide intent, cost basis, or whether other related entities increased/decreased holdings around the same time.

Relevance 9/10Novelty 5/10Timing: after-hours/filing update on 2026-07-16 for a 2026-07-14 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Celcuity Inc. (CELC) reported by Baker Bros. Advisors LP as an indirect holding.

Company-level read

Ticker impact

$CELCNeutralMedium confidence
Context

Celcuity (CELC) disclosed a $317.75M indirect open-market sale by Baker Bros. Advisors on 3.1M shares at $102.50.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction disclosure with no 10b5-1 plan and no accompanying company-specific operational or guidance change in the text.

Market effects

Sector

Limited sector read-through because the disclosure is company-specific and does not cite industry/regulatory developments.

Regional

None indicated; this is a US-listed issuer Form 4.

Global

None indicated.

Counterpoint

What could challenge this read

The sale is indirect and may reflect portfolio rebalancing or tax/liquidity needs rather than a bearish view on Celcuity’s fundamentals.

Key entities

  • issuer
    Celcuity Inc.

    Subject of the Form 4 disclosure; shares sold indirectly by Baker Bros. Advisors LP.

  • reporting entity
    Baker Bros. Advisors LP

    Reported the indirect open-market sale of 3,100,000 CELC shares.

  • filing
    SEC Form 4

    Primary-source disclosure of insider transaction details, filed 2026-07-16.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CELC insider trading history →

Related articles

SEP 1
$CELCHighAI 8/10

How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer

Celcuity Inc. (CELC) submitted an sNDA for REVTORPYK (gedatolisib) to treat HR+/HER2- advanced breast cancer with PIK3CA mutations, based on positive Phase 3 trial data. If approved, it would be the first therapy targeting all class I PI3K isoforms and both mTOR complexes. The company projects $817.9M revenue and $267.5M earnings by 2029, up from current losses. The sNDA builds on the July 2026 approval for non-mutant cases, potentially expanding market reach.

simplywall.st2 min
AUG 30
$CELCMedAI 8/10

What Could Celcuity (CELC) Gain If The FDA Clears REVTORPYK For Breast Cancer?

Celcuity (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK to treat advanced breast cancer with PIK3CA mutations. The filing is supported by Phase 3 trial results showing improved progression-free survival. If approved, REVTORPYK could become the first therapy for this indication, potentially expanding Celcuity's market. Management estimates a US$5b to US$6b addressable market and potential peak revenue of US$2.5b to US$3b for gedatolisib in this setting.

simplywall.st2 min
AUG 26
$CELCMedAI 8/10

Celcuity Submits SNDA To FDA For REVTORPYK In Advanced Breast Cancer

Celcuity Inc. (CELC) submitted a supplemental New Drug Application to the FDA for REVTORPYK, an investigational therapy for advanced breast cancer with a PIK3CA mutation. The application is supported by Phase 3 trial data showing significant improvements in progression-free survival and response rates. If approved, REVTORPYK would be the first therapy of its kind for this patient population. CELC stock closed at $92.27, up 1.63%.

rttnews.com1 min
AUG 24
$CELCLow

How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance

Celcuity Inc. (CELC) reported a net loss of $78.86 million in Q2 2026, with first-half losses widening to $131.71 million. The company is advancing gedatolisib and preparing for commercialization, with FDA approval of REVTORPYK in July. Investors focus on whether REVTORPYK revenue can offset increased cash burn. Celcuity projects $817.9 million revenue and $267.5 million earnings by 2029, implying a 77% upside from current prices.

simplywall.st3 min
AUG 20
$CELCMed

Celcuity (CELC) Q2 2026 Earnings Call Transcript

Celcuity (CELC) reported Q2 2026 net loss of $78.9M ($1.44/ share), up from $45.3M last year. Cash reserves total $754M, with $557.2M raised from a convertible note offering. The company launched Revtopik, a drug for advanced breast cancer, and plans a supplemental New Drug Application. Clinical trials showed significant reduction in disease progression risk. Management expects cash to fund operations into 2029.

fool.com3 min